

Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**" or the "**Company**") hereby informs about the following

RELEVANT EVENT

Grifols informs about the acquisition of 49% of the voting rights in Access Biologicals LLC ("**Access Biologicals**"), a company based in San Diego, California, USA, for the amount of \$51M. Grifols has entered into an option agreement to purchase the remaining 51% voting rights in five years, in 2022. Grifols has also signed a supply agreement to sell to Access Biologicals biological products not meant for human use.

The principal business activity of Access Biologicals is the collection and manufacturing of an extensive portfolio of biological products. Combined with closed-loop material sourcing, it provides critical support for various markets such as *in-vitro* diagnostic manufacturing, biopharmaceutical, cell culture and diagnostic research & development.

The purpose of this acquisition is to enhance the activity of the Bio Supplies Division (previously known as Raw Materials).

In Barcelona, on 12 January 2017

Nuria Martín Barnés
Secretary to the Board of Directors